Dietary Supplement Boosts Hair Loss Treatment Efficacy
Summary of AGA-P Supplement trial for Androgenetic Alopecia
Here’s a breakdown of the key facts from the provided text:
What was studied?
A novel dietary supplement called AGA-P (containing Serenoa repens extract, Cucurbita pepo extract, L-Cystine, and Vitamin C) was investigated for its ability to increase the effectiveness of standard treatments for androgenic alopecia (AGA) in both men and women (including female androgenic alopecia – FAGA).Why is this important?
AGA-P’s ingredients are believed to be beneficial: L-Cystine is essential for keratin synthesis.
The goal was to see if adding AGA-P to existing treatments (minoxidil and/or finasteride) would lead to better clinical betterment.
How was the study conducted?
Design: multi-center, randomized, assessor-blinded clinical trial.
Duration: 6 months (March 2024 – April 2025).
Location: 13 dermatology outpatient clinics in Italy.
Participants: 225 individuals with mild-to-severe AGA or FAGA. Mean age: 40 ± 14 years (range 18-74).
group A (106 subjects): Pharmacologic therapy + daily AGA-P capsule (82 men, 24 women).
group B (119 subjects): Pharmacologic therapy alone (83 men, 36 women).
Diagnosis Criteria: Hamilton-Norwood stages II-VII (men) or Ludwig stages II1-Advanced (women).
Assessment: Clinical improvement was assessed using a seven-point Global Assessment Scale (GAS).
Key Hypothesis:
adding AGA-P to pharmacological treatments will increase* the rate of clinical improvement.